➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
Merck
Boehringer Ingelheim
Moodys

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022511


Email this page to a colleague

« Back to Dashboard

NDA 022511 describes VIMOVO, which is a drug marketed by Horizon and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VIMOVO profile page.

The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.
Summary for 022511
Tradename:VIMOVO
Applicant:Horizon
Ingredient:esomeprazole magnesium; naproxen
Patents:11
Suppliers and Packaging for NDA: 022511
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511 NDA AUTHORIZED GENERIC Lupin Pharmaceuticals, Inc. 70748-215 70748-215-07 60 TABLET, DELAYED RELEASE in 1 BOTTLE (70748-215-07)
VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511 NDA AUTHORIZED GENERIC Lupin Pharmaceuticals, Inc. 70748-216 70748-216-07 60 TABLET, DELAYED RELEASE in 1 BOTTLE (70748-216-07)
Paragraph IV (Patent) Challenges for 022511
Tradename Dosage Ingredient NDA Submissiondate
VIMOVO TABLET, DELAYED RELEASE;ORAL esomeprazole magnesium; naproxen 022511 2010-11-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrengthEQ 20MG BASE;500MG
Approval Date:Apr 30, 2010TE:ABRLD:Yes
Patent:⤷  Try it FreePatent Expiration:Feb 28, 2023Product Flag?YSubstance Flag?Delist Request?
Patented Use:RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
Patent:⤷  Try it FreePatent Expiration:May 31, 2022Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Try it FreePatent Expiration:May 31, 2022Product Flag?YSubstance Flag?Delist Request?
Patented Use:RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

Expired US Patents for NDA 022511

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 ⤷  Try it Free ⤷  Try it Free
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 ⤷  Try it Free ⤷  Try it Free
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 ⤷  Try it Free ⤷  Try it Free
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 ⤷  Try it Free ⤷  Try it Free
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKinsey
AstraZeneca
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.